Senti Biosciences, Inc.
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.
Yvonne Li was appointed as Interim Chief Financial Officer and will assume the duties of the Chief Financial Officer, effective May 4, 2024
Timothy Lu, M.D., Ph.D., the Chief Executive Officer and President of the Company, was appointed to serve as the interim principal financial officer and principal accounting officer of the Company, effective as of May 4, 2024
Extracted from this filing and checked against the source text.
Yvonne Li was appointed as Interim Chief Financial Officer at Senti Biosciences, Inc..
Yvonne Li was appointed as Interim Chief Financial Officer and will assume the duties of the Chief Financial Officer, effective May 4, 2024View on SEC.gov
Timothy Lu was appointed as interim principal financial officer and principal accounting officer at Senti Biosciences, Inc..
Timothy Lu, M.D., Ph.D., the Chief Executive Officer and President of the Company, was appointed to serve as the interim principal financial officer and principal accounting officer of the Company, effective as of May 4, 2024View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.